May 9th 2024
Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Mirvetuximab Soravtansine Shows Survival Benefit in Ovarian Cancer Subtype
May 4th 2023Based on findings from the phase 3 MIRASOL trial, investigators plan to submit a supplemental biologics license application for mirvetuximab soravtansine in folate receptor α–positive platinum-resistant ovarian cancer.
Cryocompression Use by Multidisciplinary Teams May Help Gynecologic Cancer QOL
April 26th 2023Medical oncologists and gynecologic oncologists alike have a shared responsibility to help treat symptoms of neuropathy in patients undergoing chemotherapy for gynecologic cancer, according to an expert from Duke University Medical Center.
Cryocompression May Mitigate Chemo-Induced Neuropathy in Gynecologic Cancers
April 20th 2023Investigators report that most patients with gynecologic cancers were able to tolerate cryocompression to help manage chemotherapy-induced neuropathy, according to an expert from Duke University Medical Center.
Vaccine-Chemoradiotherapy Combo Produces 100% Clinical Response in Advanced Cervical Cancer
November 15th 2022Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.